secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001619856-22-000019
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Q3 net loss $26.6M, cash $342.6M; CB-011 IND submitted, CB-010 ODD for FL
--------------------------------------------------------------------------------

- Net loss $26.6M vs $21.0M YoY; revenue $3.3M (down from $4.0M) on lower AbbVie collaboration revenue.
- Cash, cash equivalents, and marketable securities $342.6M as of Sept 30, 2022, down from $413.5M at Dec 31, 2021.
- CB-010 ANTLER Phase 1 trial enrolling at dose level 2; ODD for follicular lymphoma granted Sept 2022.
- CB-011 IND for relapsed/refractory multiple myeloma submitted to FDA in Q4 2022; FDA response expected by YE 2022.
- CB-012 IND for r/r AML expected in 2023; CB-020 target selection for CAR-NK solid tumors expected Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985622000019/0001619856-22-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985622000019/crbu-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001619856-22-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer